Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Last updated: August 20, 2026 Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met both its recurrence free survival
Trump is expected to nominate Heidi Overton as FDA commissioner; Amylyx’s avexitide cut serious hypoglycemic events 55% in Phase 3 LUCIDITY; BioMarin pays $275M upfront for Alesta; LEO buys dersimelagon for up to $435M; Sandoz and Henlius sign a $322M biosimilar deal; a third death in China’s investigator initiated trials.
EyePoint’s Duravyu missed the LUGANO primary endpoint in wet AMD on the full dataset, clearing non inferiority only after excluding 9 of 211 patients. AstraZeneca stopped its Phase 3 volrustomig lung cancer trial and reported SAFFRON and DESTINY-Lung04 wins the same day. Full tables, the Slate and Fulcrum reverse merger terms, and the Lilly OmniAb deal.
Last updated: August 17, 2026 Capricor Therapeutics says the FDA is willing to review an amended deramiocel BLA and extend the August 22, 2026 action
Last updated: August 14, 2026 In an August 13 bankruptcy auction, PTC Therapeutics agreed to pay up to $211 million for Sangamo’s Fabry disease gene
Last updated: August 13, 2026 Definium Therapeutics’ DT120, an orally disintegrating tablet of lysergide, reduced Hamilton Anxiety Rating Scale scores by 11.6 points versus 6.2
Last updated: August 12, 2026 The FDA rejected ITM’s radioligand therapy ITM-11 and forced Scholar Rock to drop a fill finish site from its apitegromab
Sionna’s SION-719 missed on sweat chloride as a Trikafta add on. Full data on the miss, Tenax’s Phase 3, Silence’s PV win, and Grail’s FDA panel date.
Last updated: August 10, 2026 Quick answer: The FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) on August 6, 2026, in combination with nivolumab
Last updated: August 7, 2026 Quick answer: Eli Lilly reported $23 billion in second quarter 2026 revenue, with shares rising nearly 5% to $1,170 and
